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Abstract  
Background  
A serogroup B meningococcal vaccine (4CMenB) is licensed for infant use in countries 
including Canada, Australia and those of the European Union. Data on serum bactericidal 
antibody (hSBA) waning and the ideal timing of a ‘toddler’ booster dose are essential to 
optimise vaccine utilization. 
Methods 
An open-labeled, multicenter phase-2b follow-on European study conducted from 2009 to 
2012. Participants previously receiving 4CMenB with routine vaccines at 2,4,6 or 2,3,4 
months (246Con and 234Con) or at 2,4,6 months intercalated with routine vaccines (246Int) 
received a booster dose at 12, 18 or 24 months. 4CMenB-naïve ‘Control’ participants aged 
12, 18 or 24 months received two doses of 4CMenB two months apart.  
Results 
1588 participants were recruited. At 12 months, prior to any booster doses, the proportions 
with hSBA titers ≥ 1:5 for strain 44/76-SL (testing vaccine component fHBP) were 73% 
(120/165) for the ‘246Con’ group, 85% (125/147) for ‘246Int’, 57% (51/90) for ‘234Con’ 
and 13% (26/199) for Controls. For strain 5/99 (NadA) proportions were ≥ 96% (all 
4CMenB-recipients) and 1% (Controls). For strain NZ98/254 (PorA) these were 18-35% 
(4CMenB-recipients) and 1% (Controls). By 24 months, 4CMenB-recipient proportions were 
13%–22% (44/76-SL), 82%-94% (5/99) and 7-13% (NZ98/254) and in Controls ≤ 4%. 
Following a 12-month booster-dose ≥ 95% of previously immunized participants had titers 
≥1:5 (all strains).  
Conclusions 
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A 4CMenB booster-dose can overcome waning hSBA titers after early-infant immunization. 
Administration at 12 months could help to maintain immunity during an age of high risk, and 
the persistence of this response requires further study. 
Funding: Novartis Vaccines and Diagnostics 
  
 5 
Introduction 
The recent licensing of a novel vaccine against serogroup B meningococcal disease 
(4CMenB) by the USA food and drug administration (FDA) for individuals aged between 10 
and 25 years (1), by the EMA from 2 months of age in the European Union (2), and 
administration to  over 45,000 individuals aged 2 months to 20 years in the Saguenay-Lac 
Saint-Jean region of Quebec (3) are important steps towards the prevention of this potentially 
fatal infection. It has also been recommended that the vaccine be introduced into the UK 
routine infant immunization schedule (4, 5). An important consideration in cost-effectiveness 
calculations is whether the selected schedule can maintain protection during the early years of 
life. This in turn is likely to be dependent on the persistence of antibodies following 
immunization, as an association between waning antibodies and reduced vaccine 
effectiveness has been seen both for conjugate vaccines against serogroup C (6) and for outer 
membrane vaccines against serogroup B (7-9).  
In a pre-licensure study participants received 4CMenB at 2, 4, 6 months of age (alone or with 
routine concomitant vaccines) or at 2, 3, 4 months of age (with concomitant vaccines) (10). 
This study design provided the opportunity to assess the rate of bactericidal antibody waning 
after a range of infant 4CMenB immunization schedules, and accordingly a follow-on study 
was performed to assess maintenance of vaccine-induced bactericidal antibodies to 12 
months of age and beyond, as well as the immunogenicity of a booster dose of 4CMenB 
when administered at 12, 18 or 24 months of age 
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Methods 
Study participants and trial design 
This follow-on study of a phase IIb, open-label, randomized, parallel-group controlled trial 
was conducted between July 2009 and January 2012 in Belgium (6 centers), UK (4 centers), 
Czech Republic (4 centers), Germany (24 centers), Italy (5 centers) and Spain (16 centers). 
Appropriate regulatory authorities in each participating country granted approval for the trial. 
As previously described, participants in the parent study were randomised 2:2:1:1 to receive: 
4CMenB concomitantly with routine immunization at 2, 4, and 6 months of age (246Con), 
4CMenB at 2, 4, 6 months of age, intercalated to routine vaccines at 3, 5, 7 months of age 
(246Int), 4CMenB with routine vaccine at 2, 3, 4 months (234Con) or routine vaccines alone 
(Control)(10). At the last visit in this study participants’ parents were invited to enrol their 
child into the follow-on study. Following parental informed consent, enrolled ‘follow-on’ 
participants who previously received 4CMenB were randomised 1:1:1 to receive a booster 
dose of 4CMenB at 12, 18 or 24 months of age (see Figure1) according to a centrally held 
randomization list (Novartis) using fixed block size of 3. Randomization in the follow-on 
study occurred prior to enrollment based on the participants completing the parent study, but 
follow-on randomization group was to have been concealed from parents up until the time of 
enrollment. Those who previously received routine vaccines alone received 4CMenB at 12 
and 14 months of age (Control 12, 14). Additionally, two groups of 50 ‘Control’ participants 
who were 4CMenB naïve were to be recruited to receive 4CMenB at 18 and 20 (Control 18, 
20), or 24 and 26 months of age (Control 24, 26). Blood tests were taken immediately before 
the first dose of 4CMenB and one month after each dose. 
Exclusion criteria were any history of meningococcal infection or close contact with someone 
experiencing meningococcal disease, prior receipt of meningococcal B (control participants 
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only) vaccines, acute or chronic illness, known reactions to vaccine components, known or 
suspected immune disease or impairment including the administration of steroids, receipt of 
antibiotics 6 days prior to enrollment, receipt of blood products or planned receipt of non-
study vaccines (supplementary Table 1) 
In the UK control participants were recruited by information letters sent via National Health 
Service child health computer databases while those in other study centers were recruited 
through paediatric hospitals or private practices.  
Intervention 
4CMenB consists of 50µg each of Neisserial adhesin A (NadA), and fusion proteins 
containing Neisseria Heparin Binding Antigen (NHBA) and Factor H Binding Protein 
(fHbp), 25 µg detoxified OMV from N. meningitidis strain NZ98/254, 1.5 mg aluminium 
hydroxide and 10 mM histidine in 0.5 ml water for injection. All vaccines were administered 
by intramuscular injection in the antero-lateral thigh. In order to maintain participant’s 
immunizations in line with their country’s immunizations programme, routine immunizations 
were offered as per supplementary Table 2, but did not form part of the study evaluation. 
These vaccines were not administered within 30 days of the study vaccines.  
Functional antibody  
Serum bactericidal activity using human complement (hSBA) was assessed at the Novartis 
Vaccines Serology Laboratory, Marburg, Germany against three reference strains chosen to 
determine the immunogenicity of individual vaccine components—strain 44/76-SL for fHbp, 
strain 5/99 for NadA and strain NZ98/254 for OMV. A strain not included in the original 
study (M10713) was used to assess the immunogenicity of NHBA as previously 
described(11). hSBA was expressed as interpolated titers according to reciprocal serum 
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dilutions yielding 50% or greater killing of the target strain after 60 minutes of incubation 
compared with growth at time 0. An interpolated titer ≥ 1:5 represented 95% confidence that 
participants achieving this titer had a protective hSBA (≥1:4).(12)  
Safety  
Parents recorded local injection site (pain, erythema, swelling and induration) and systemic 
reactions (i.e. fever [axillary temperature ≥ 38°C], change in eating habits, sleepiness, 
unusual crying, vomiting, diarrhea, irritability, rash) for seven days after each vaccination. 
Injection site pain was classified by the parents as mild (minor reaction to touch), moderate 
(cried or protested when touched), or severe (pain on limb movement). Erythema, induration 
and swelling were summarized by maximal severity (1-25 mm, 25-50 mm and >50 mm). 
Adverse event recording was enhanced by telephone contact in the week after study 
vaccination. Safety follow-ups were completed 6 months after the last dose of 4CMenB. All 
serious adverse events (SAEs) reported during the study were recorded. Determination of the 
relationship between adverse events and the study vaccine was made by the study site’s 
investigator judgment based on temporal relationship and biological plausibility criteria.   
Statistics 
The pre-specified population for the immunogenicity analysis was the per-protocol (PP) 
population, analysed as per-immunization course received and including all those receiving 
all the relevant vaccine doses correctly, provided evaluable serum samples at the relevant 
timepoints and had no protocol violations having a significant impact on immunogenicity 
analysis.  
The proportions of participants with hSBA≥ 1:5 for the reference strains were calculated, as 
were the 2-sided 98.3% Clopper Pearson confidence intervals (CI). In addition, hSBA titers 
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were log transformed and their geometric mean titers (GMTs) and 2-sided 95% CI calculated, 
as were the between-group ratios of GMTs and 2-sided 95% CIs (using two-way analysis of 
variance with a factor for vaccine group and country). 
The primary outcome was the proportion of participants in the 246Con group with hSBA 
titers ≥ 1:5 for strains 44/76-SL, NZ98/254 and 5/99 following a booster dose of 4CMenB at 
12, 18 or 24 months of age. A sufficient immune response was pre-specified as the lower 
limit of the 98.3% confidence interval for this proportion being above 75% for at least one of 
the booster dose timings. Based on previous immunogenicity studies, indicating a likely 
‘true’ rate of 90% for participants having hSBA ≥ 1:5 (13), performing 5000 simulations 
suggested a sample size of 180 participants would provide 99% power to demonstrate this. 
The main secondary outcomes were the proportions with hSBA titers ≥1:5 and hSBA GMTs 
before the booster dose in the above participants, and before and after the booster dose for 
246Int and 234Con participants. The induction of immunological memory was assessed by 
comparison of the response to a single dose of 4CMenB at 12, 18 or 24 months in participants 
previously immunized in infancy and those who were MenB vaccine naïve. The 
immunogenicity of 2 doses of 4CMenB given at 12 and 14, 18 and 20 and 24 and 26 months 
was also assessed. The above measures of hSBA activity against strain M10713 were 
determined as a post-hoc analysis.  
Individuals who received at least one dose of vaccine and provided post-baseline safety data 
were included in the safety analyses, for which results were reported descriptively with no 
formal statistical analyses. Safety objectives were the tolerability of a booster dose of 
4CMenB at 12, 18 or 24 months of age, and of a 2 dose schedule commencing at these ages 
in MenB vaccine naïve children. 
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Statistical analysis was performed using SAS version 9.1. (SAS Institute, Cary, NC). 
Results 
1799 participants completed the parent study, of whom 1481were enrolled into this study and 
randomised to a booster dose at 12, 18 or 24 months of age. In addition, 51 new participants 
were recruited at 18 months, and 56 at 24 months (Figure 1). Of these 1588 participants, 826 
(52%) were male and 94% were Caucasian.  
1495 (94%) participants completed the study, the withdrawals primarily being due to 
withdrawal of consent (41), loss to follow up (26), protocol deviations (14) and inappropriate 
enrollment (7). There was one death in a child following a car accident, prior to receipt of 
study vaccine. The PP population for immunogenicity included 1221 (76%) of enrolled 
participants, and the safety analysis population included 1519 (96%). 
Immunogenicity 
Primary outcome 
The proportion of 246Con participants with hSBA ≥ 1:5 following a booster dose of 4CMenB 
at 12 months of age was 97% (93 – 99) for strain 44/76-SL, 100% (97 – 100) for strain 5/99 
and 95% (89 – 98) for strain NZ98/254 (Table 1). As the lower 98.3% confidence limit for 
these proportions was above 75% for all three strains, the primary objective for the study was 
met. hSBA titres for this group following a booster dose at 18 and 24 months are also shown 
in Table 1 (a). 
Secondary objectives 
The proportions with hSBA ≥ 1:5 following the booster dose of 4CMenB administered at 12, 
18 and 24 months to participants in groups 246Int and 234Con were similar to those in the 
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246Con group outlined above, being 98% or greater for strains 44/76-SL and 5/99, and 80 to 
97% for strain NZ98/254 (Table 1 (a)).  
Prior to administration of the booster doses at 12, 18 and 24 months of age progressive 
waning of these proportions was observed for all groups for strains 44/76-SL and NZ98/254, 
with waning particularly rapid for the latter strain (no greater than 13% by 18 months of age). 
In 4CMenB vaccine naïve control participants, prior to immunization the proportion of 
participants with hSBA ≥ 1:5 were no higher than 13% for strains 44/76-SL, NZ98/254 and 
5/99. 
For the control participants, a two-dose immunization schedule resulted in at least 91% of 
recipients having hSBA ≥ 1:5 for strains 44/76-SL, 5/99 and NZ98/254.  
As a post-hoc analysis, strain M10713 hSBA titers for a subset of participants in the 234Con 
group and the Control groups were determined. Pre-booster dose, the proportions of these 
participants with hSBA ≥ 1:5 were similar regardless of whether they had been primed with 
4CMenB or not. (Table 1 (a))  
hSBA GMTs are demonstrated in Figure 2 and Table 1 (b). For all strains, a greater rise in 
hSBA GMTs was seen following a single dose of 4CMenB in participants previously primed 
with this vaccine than in control recipients. 
All control participants receiving two doses of 4CMenB achieved hSBA ≥ 1:5 for strains 
44/76-SL and 5/99; for NZ98/254 this proportion ranged from 91% to 99%, and for M10713 
was 86% (Control 18, 20) and 81% (Control 24, 26).  
Rates of fever following a single dose of 4CMenB ranged from 20% to 45% and were similar 
in children receiving 4CMenB for the first or fourth time (Figure 3). A trend to increasing 
reported rates of severe tenderness at the injection site with increasing age was also apparent 
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(Figure 3); again, this was not influenced by the number of previous doses of 4CMenB 
received. 
During the study 70 serious adverse events affecting 58 participants were reported (including 
the death mentioned above).  Three of these were classified by investigators as possibly being 
related to the study vaccine. One child enrolled into the Control 12, 14 month group, was 
diagnosed with autism at the age of 3 years, having initially presented with speech delay and 
learning difficulties at age 18 months. This child was immunised with his routine vaccines (as 
per UK schedule) at 12 and 14 months of age, and with 4CMenB at 15 and 17 months of age. 
The investigator considered it was not possible to exclude a relationship with the study 
vaccine given the temporal association.  This child’s previous medical history was 
unremarkable, and speech and hearing assessments were normal. At 3 ½ years of age the 
child had persistent difficulties with language development and social interaction.  A second 
child, in the 246Con-24 group, developed idiopathic epilepsy, with the first convulsion at age 
2 years and 3 months, 106 days after the booster dose of vaccine at 24 months of age. EEG 
and MRI tests were normal. By the age of 3 ½ years the child had experienced six seizures 
(both febrile and afebrile), but none within the last 3 months. There was no developmental 
delay and the child was not receiving anticonvulsant therapy. A third child (Control 12, 14) 
developed two febrile convulsions on the day of the 12 month immunization, and was also 
diagnosed with atypical pneumonia at the time of presentation. 
Discussion 
This study of over 1500 participants provides novel data on the persistence through the 
second year of life of bactericidal antibody induced by various infant 4CMenB immunization 
regimens and on the immunogenicity and reactogenicity profile of 4CMenB given as two 
doses in the second year of life. These data, combined with local age-specific epidemiology, 
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are vital for the design of the optimal strategies for implementation of 4CMenB 
immunization programmes. 
The UK Joint Committee on Vaccines and Immunization (JCVI) recently recommended that 
4CMenB be introduced in a 2, 4, 12 month immunization schedule into the routine infant 
immunization program (4, 5). Specific studies of the immunogenicity of this ‘2 +1’ schedule 
are currently underway(14). However, the European Medicines Agency marketing 
authorisation for the vaccine is for a 3-dose priming schedule with a booster in the second 
year of life (3+1), a schedule which was informed by the data presented in this study(2) and 
which may be selected by some national authorities. 
Importantly, in the current study the proportions of participants with SBA titers ≥ 1:5 prior to 
boosting in the second year of life was not influenced by whether the last priming vaccine 
was given at 4 or 6 months of age. For both schedules the response to a single booster dose of 
4CMenB was also similar and this, combined with the relatively lower hSBA GMTs 
following the first dose of 4CMenB in control participants, suggests both schedules 
effectively induced immunological memory. 
These data provide reassurance that 4CMenB could be incorporated into either a 2, 4, 6 
month schedule (as used in North America, Latin America and many European countries) or 
into an accelerated 2, 3, 4 dose schedule without impacting on the persistence of immune 
protection through the first year of life or following the booster dose.  
The study also informs the optimal timing of the booster dose. The ongoing waning of 
antibodies observed from 1 to 2 years of age in the second year of life is of some concern 
given the incidence of serogroup B meningocococcal disease at this age is second only to 
infancy in Europe(15) and suggests that where this is the case booster dose should not be 
delayed beyond 12 month. Whether or not this disadvantage could be offset by greater 
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persistence of antibodies through pre-school years following a delayed dose is not currently 
known, and is being evaluated in a further persistence study(16).  
The licensed schedule for 4CMenB includes two doses given two months apart for children 
aged 12 months to 10 years, with a booster dose given 1 to 2 years later for children initially 
immunized at 12 to 23 months (17). These data demonstrate that, although 88% or more of 
children developed SBA titres ≥ 1:5 for strains 44/76 and 5/99 after a single dose, a two dose 
priming schedule is required to be immunogenic for all 4 strains, supporting the licensed 
schedule for his age group. There was little apparent difference in immunogenicity across this 
age band.   
There was also little difference in the reactogenicity profile between controls immunized at 
12, 18 or 24 months, with the exception of a trend to higher rates of reported severe 
tenderness in older children. This trend was also noted with increasing age of the booster 
dose. It is possible that this reflects a trend to greater local reactogenicity with greater age, 
however an alternative possibility is that severe tenderness (i.e. tenderness on limb 
movement) might be more readily reported as the developing child becomes increasingly 
verbal. The rates of fever following 4CMenB given in the second year of life were similar to 
those reported when this vaccine was given without concomitant vaccines in infancy (10), 
however they are higher than those reported following glyco-conjugate vaccines such as 
MenC given to one to two year olds (18-20). This tendency for the vaccine to be relatively 
reactogenic compared to other routinely used childhood immunisations has been described in 
previous clinical trials, and in the UK parents are advised to routinely administer paracetamol 
prophylactically when their child receives their 2 and 4 month 4CMenB immunisations(21). 
No such recommendation is given for the 12 month booster immunisation, although this was 
accompanied by fever rates of 30% to 45% in our study. 
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The bactericidal titers against the M10713 strain, included as a post-hoc assessment of the 
immunogenicity of the NHBA component, warrant specific consideration. Only 36% of 
participants developed bactericidal antibodies against this strain following a 2, 3, 4 month 
schedule, and hSBA titres were similar to those of controls following priming and prior to 
boosting. Direct comparisons of immunogenicity against M10713 for 234 and 246 schedules 
were not possible within this study, however, for a previously reported study over 80% of 
participants receiving a 2, 4, 6 schedule had hSBA ≥ 1:5 for this strain, which was maintained 
at 60% prior to boosting at 12 months(22). Within the limits of cross-study comparisons this 
does suggest that, for this antigen at least, a 2, 4, 6 month schedule may be preferable. It is 
worth noting that, as for the other strains, a greater rise in M10713 specific bactericidal 
antibodies was seen among primed infants than in those receiving this for the first time, again 
suggestive of immunological memory.  
The data obtained in this study on antibody persistence after primary immunization in the 
absence of a booster dose, complement those obtained in other studies after a 4CMenB 
toddler booster dose (11, 23), a further booster dose at 3 ½ years of age (24), primary 
immunization at 3 ½ years of age (24) and primary immunization in adolescence (25). As 
with meningococcal conjugate vaccines (26), antibody persistence appears to be enhanced 
with increasing age at primary immunization. 
Another feature is the variable rate of waning between different strains, with bactericidal 
titers against strain 5/99 (NadA) being maintained in the majority of vaccine recipients while 
those against NZ98/254 (PorA) waned more rapidly, and an intermediate rate of waning 
observed for strains 44/76 (fHBP) and M10713 (NHBA). This pattern of SBA waning has 
been highly consistent across multiple studies (11, 23, 24, 27) . In the absence of any data on 
whether relatively persistent SBA titres are reflected in more prolonged immunity against 
strains bearing the relevant antigens, is unclear whether this is likely to be clinically relevant 
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or merely reflects different susceptibilities of the strains to killing in the serum bactericidal 
antibody assay.  
This differential rate of waning has made predicting persistence of the immune protection 
provided by immunization with 4CMenB particularly difficult. The interim statement by the 
JCVI published in July 2013 suggested that infant immunization with this vaccine would 
directly prevent approximately 25% of the lifetime risk of invasive MenB disease in the UK 
(28). Should the vaccine be introduced into routine infant immunization, extensive post-
implementation surveillance is already planned to monitor the accuracy of such predictions 
(29), and whether strains bearing antigens targeted by ‘waning’ antibodies will be over-
represented as a cause of secondary vaccine failures.  
A limitation of this study was the lower numbers of participants at the 18 and 24 month time 
points. This in part reflected an increasing number of withdrawals with advancing age of 
booster immunization, reflecting greater interval between enrollment and immunization, but 
also appears to reflect a discrepancy in numbers recruited to different randomised groups at 
the conclusion of the parent study. This may in turn reflect a problem with concealment of 
randomisation group from the parents prior to enrollment. Of note is that although the routine 
vaccines administered during the study did differ between countries, these vaccines were not 
administered within 30 days of the study vaccine. In the parent study we demonstrated that 
routine glyco-conjugate and diphtheria, tetanus, pertussis and polio vaccines had minimal 
impact on 4CMenB immunogenicity, even when administered concomitantly(10).  It is 
therefore highly unlikely these variable routine immunization schedules would have 
influenced the 4CMenB immunogenicity profile in this study. 
Nevertheless, this study makes an important contribution to the expanding body of 
knowledge regarding 4CMenB. The recent 4CMenB mass immunization campaigns at 
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Princeton University (30), University of California, Santa Barbara (31) and Saguenay-Lac 
Saint Jean, Quebe(3), highlight the importance of a vaccine being available against this 
rapidly fatal infection. Information on duration of immunity is essential to plan schedules and 
provide understanding of how to best use this vaccine. Our data support the use of a booster 
dose early in the second year of life following infant immunization, and the need for further 
studies to look at ongoing antibody persistence beyond the time points measured in this 
study.  Nonetheless, as with other vaccines licensed based on immunologic surrogate 
measures, a firm understanding of the duration of protection will only be established after 
broad vaccine implementation with robust disease surveillance and vaccine coverage 
assessments.  
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Figure 1: Study design and participant numbers 
Abbreviations: rand, randomized; imm, immunized; comp, completed.  
Routine vaccines in the parent study were a combination diphtheria, tetanus toxoid, acellular 
pertussis, Haemophilus inflluenza type b, Hepatitis B and inactivated polio vaccine 
(DTapHib-HepB-IPV) and 7-valent pneumococcal vaccine. 
Figure 2:  
Serum bactericidal activity geometric mean titers by strain and age at booster dose 
Figure 3: 
Rates of systemic (figure 3a) and local (figure 3b) reactions following immunization at ages 
shown. 
